#VG-3927

16 Oct 2026

Oral TREM2 Agonist Shows Safety and Early Signals in Alzheimer’s Phase I Trial

A new oral drug that activates microglial TREM2 shows safety and early efficacy signals in a Phase I trial for Alzheimer’s disease.

Read more